FDA 510(k) Clearance Expands Labelling of MolecuLight i:X® to Include the Ability to Identify Regions Containing Elevated Load and More Bacterial Species

New FDA Clearance Illustrates the Utility of the i:X to Reliably Detect
Clinically Significant Bacteria that Impedes Wound Healing

TORONTO, June 29, 2022 /PRNewswire/ --  MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that it has received an expansion to its FDA 510(k) clearance for the MolecuLight i:X® imaging device's ability to detect the location of elevated bacterial loads (>10⁴ CFU/g) in wounds. The expanded labelling also includes the device's ability to identify areas of wounds containing more bacterial species, including key target pathogens of interest to the CDC that are major causes of antimicrobial resistance¹. Detectable species include gram-negative and gram-positive species, aerobes and anaerobes. This expanded labeling is based on a detailed retrospective statistical analysis of over 350 patients.

"We are thrilled with the FDA's new clearance for MolecuLight' ability to determine the location of elevated bacterial loads in wounds, in addition to the ability to identify regions with more bacterial species of interest", says Anil Amlani, MolecuLight's CEO. "Clinicians worldwide are using the MolecuLight device to visualize regions with clinically significant bacterial loads and more species of concern. With point-of-care information on bacterial load and its locations through use of a MolecuLight device, clinicians can act immediately to tailor their cleaning, debridement, antimicrobial strategies and treatments accordingly."

This video (courtesy of Rose Raizman) illustrates the importance of visualizing the location of elevated bacterial load in a wound. In this scenario, the clinician is using MolecuLight i:X to inform their decision-making and target their wound hygiene to the areas of red fluorescence. Regions of red, indicating that the wound contains clinically significant (>10⁴ CFU/g) levels of bacterial burden, are clearly visible on the patient's diabetic foot ulcer (see image).     

In addition, the FDA has also recognized MolecuLight's ability to visualize regions containing troublesome bacterial species at the point-of-care. The MolecuLight device can be used to enable fluorescence-guided tissue biopsies to these regions to detect a higher number of pathogens of interest (defined by the CDC as increasing risk to develop antibiotic resistance) compared to standard-of-care-guided biopsies. The CDC has identified antibiotic resistance as "one of the greatest global public health challenges of our time"¹. Strategies to combat antibiotic resistance include containing emerging threats through early detection and aggressive response and improving appropriate antibiotic use through antimicrobial stewardship programs. The expanded use of diagnostic tools, like MolecuLight, to improve accuracy and speed of pathogen detection has been called out to help improve appropriate antibiotic selection and reduce unnecessary antibiotic use¹.

MolecuLight was the first to receive FDA de novo clearance for its MolecuLight i:X imaging platform and has subsequently received three additional FDA 510(k) clearances for the device.

MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight's suite of commercially released devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection and localization of elevated bacterial load in wounds and for digital wound measurement. MolecuLight procedures performed in the United States can benefit from an available reimbursement pathway including two CPT® codes for physician work to perform "fluorescence imaging for bacterial presence, location, and load" and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant unmet needs including food safety, consumer cosmetics and other key industrial markets.

www.moleculight.com

Image: Download at: https://moleculight.box.com/s/ax8758gz0f8amouhcjjvs4xzkfa9vofo 
Video: https://youtu.be/HKOCGBlIQj4

Rob Sandler, Chief Marketing Officer, MolecuLight Inc., T. +1.647.362.4684, rsandler@moleculight.com

Photo - https://mma.prnewswire.com/media/1849819/MolecuLight_FDA_510_k__Clearance_Expands_Labelling_of_MolecuLigh.jpg